fda warning letters compounded semaglutide 2025 september Why the Issued 30 to Telehealth Sites Marketing GLP-1s FDA warns against compounded GLP-1

Currently approved to treat type 2 diabetes and obesity, this drug class has also shown potential in other indications, from nonalcoholic fatty liver disease and cardiovascular disease to addiction, and recent studies suggest it may help tackle another big targetAlzheimers disease

Curr Drug Deliv 2019;16:793-806.ArticlePubMed 31

Endocrinology 121 (3), 10761082

1.2 Rising awareness through education and word of mouth Historically, obesity has been viewed as a behavioral issue

However, this should in no way be a hindrance to receiving the benefits of Ozempic

The amounts used in compounded semaglutide formulations are substantially lower than what research has tested for safety, typically in the range of milligrams to low grams per injection